Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment
- Hua Sun
- Song Cao
- R. Jay Mashl
- Chia-Kuei Mo
- Simone Zaccaria
- Michael C. Wendl
- Sherri R. Davies
- Matthew H. Bailey
- Tina M. Primeau
- Jeremy Hoog
- Jacqueline L. Mudd
- Dennis A. Dean
- Rajesh Patidar
- Li Chen
- Matthew A. Wyczalkowski
- Reyka G. Jayasinghe
- Fernanda Martins Rodrigues
- Nadezhda V. Terekhanova
- Yize Li
- Kian-Huat Lim
- Andrea Wang-Gillam
- Brian A. Van Tine
- Cynthia X. Ma
- Rebecca Aft
- Katherine C. Fuh
- Julie K. Schwarz
- Jose P. Zevallos
- Sidharth V. Puram
- John F. Dipersio
- The NCI PDXNet Consortium
- Brandi Davis-Dusenbery
- Matthew J. Ellis
- Michael T. Lewis
- Michael A. Davies
- Meenhard Herlyn
- Bingliang Fang
- Jack A. Roth
- Alana L. Welm
- Bryan E. Welm
- Funda Meric-Bernstam
- Feng Chen
- Ryan C. Fields
- Shunqiang Li
- Ramaswamy Govindan
- James H. Doroshow
- Jeffrey A. Moscow
- Yvonne A. Evrard
- Jeffrey H. Chuang
- Benjamin J. Raphael
- Li Ding
Publication date
August 2021
DOI Publisher
Springer Science and Business Media LLC Journal
Nature CommunicationsAbstract
Patient-derived xenograft models (PDX) have been extensively used to study the molecular and clinical features of cancers. Here the authors present a cohort of 536 PDX models from 25 cancers, as well as their genomic and evolutionary profiles and their suitability for clinical trials
Add to ORKG